Archives: Agenda

Successful biotech development is rarely about choosing between one expert or a team. It is about having access to the right expertise at the right time, supported by a model that can scale as development needs evolve.

In this session we will explore:

• The advantages and limitations of relying on a single trusted consultant versus a multidisciplinary team supporting development from IND through commercialization.
• How integrated consulting teams can bring together regulatory, clinical, CMC, biostatistics, medical writing, and market access capabilities to address evolving development needs.
• Strategies for managing increasing complexity as programs progress across functions, stakeholders, and global regions.
• How scalable consulting models can reduce execution risk through coordinated planning, quality oversight, business continuity, and access to specialized support.

The value of coordinated global perspectives across FDA, EMA, PMDA, NMPA, MHRA, and other regulatory agencies while maximizing limited internal resources.

Biotech companies often operate with lean teams and limited resources yet face the same complexities as larger pharma. This session will explore how smaller organisations can maximise internal capabilities, leverage cross-functional talent, and build efficient operating models to successfully deliver clinical trials.

• Making the most of lean teams: prioritisation and resource allocation strategies
• Leveraging cross-functional talent and transferable skillsets across departments
• Building agile operating models to increase efficiency and speed
• When to outsource vs keep capabilities in-house
• Empowering individuals to take on broader roles and responsibilities
• Creating a culture of collaboration and flexibility to drive delivery

For biotech and emerging biopharma companies, every development decision carries significant implications for timelines, funding milestones, and investor confidence. As pressure mounts to advance programs faster, the most successful organizations are using predictive analytics, integrated development planning, and data-driven decision-making to de-risk clinical development and accelerate execution across the entire development lifecycle.

Join this session to learn how biotech sponsors can reduce uncertainty from first-in-human studies through pivotal trials by reducing delays between phases, increasing cross-functional coordination, and improving operational execution to bring therapies to patients faster.

Key Discussion Points:

• Accelerating transitions between Phase I, II, and III studies
• Reducing operational “white space” between development milestones
• Increasing parallelization of clinical, regulatory, and operational workstreams
• Improving enrollment forecasting and predictability
• Driving efficiency and speed across the end-to-end development lifecycle

• Navigating traditional and niche CRO models as an emerging biotech
• Understanding the key differences between big pharma and biotech approaches to clinical trial execution and outsourcing strategy
• Examining how niche and specialist vendors are addressing sponsor pain points with more tailored, flexible solutions
• Identifying how sponsors and providers can better align expectations, communication models, and operational support for successful partnerships